OncoMatch/Clinical Trials/NCT06298968
Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
Is NCT06298968 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab for intrahepatic cholangiocarcinoma.
Treatment: combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab — In this phase 2 study, the investigators aim to evaluate the efficacy and safety of combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab for patients with advanced and unresectable intrahepatic cholangiocarcinoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
previous treatment with PD1 antibody
Cannot have received: anti-PD-L1 therapy
previous treatment with programmed death ligand -1 （PD-L1） antibody
Cannot have received: anti-CTLA-4 therapy
previous treatment with cytotoxic T lymphocyte-associated antigen-4 （CTLA4） antibody
Lab requirements
Blood counts
Neutrophils ≥1.5*10^9/L; platelets≥100*10^9/L; hemoglobin≥9g/dl; serum albumin≥3g/dl
Kidney function
serum creatinine ≤ 1.5 ULN, creatinine clearance rate ≥ 60ml / min
Liver function
bilirubin ≤ 2 times ULN; ALT and AST ≤ 2 times ULN
Functional indicators of vital organs meet the following requirements a Neutrophils ≥1.5*109/L; platelets≥100*109/L; hemoglobin≥9g/dl; serum albumin≥3g/dl; b Thyroid stimulating hormone (TSH) ≤ 1 times the upper limit of normal value(ULN), T3, T4 are in the normal range; c bilirubin ≤ 2 times ULN; Alanine aminotransferase （ALT） and Aspartate aminotransferase （AST） ≤ 2 times ULN; serum creatinine ≤ 1.5 ULN, creatinine clearance rate ≥ 60ml / min;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify